Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
VWAGY Volkswagen AG
MLVF Malvern Bancorp Inc
GBCI Glacier Bancorp Inc
Go

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Closing Price
$2.39
Day's Change
-0.01 (-0.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.60
Day's Low
2.17
Volume
(Heavy Day)
Volume:
816,733

10-day average volume:
173,568
816,733

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Palantir Technologies Inc. (PLTR) Investigation

11:01 am ET May 12, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / May 12, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Palantir Technologies Inc.("Palantir" or the "Company) (NYSE:PLTR). Investors who purchased Palantir securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pltr.

Bronstein, Gewirtz and Grossman, LLC, Thursday, May 12, 2022, Press release picture

The investigation concerns whether Palantir and certain of its officers and/or directors have violated federal securities laws.

On May 9, 2022, Palantir disclosed its financial results for the first quarter of 2022 ("Q1") and issued guidance for the second quarter of 2022 ("Q2"). For Q1, Palantir announced adjusted earnings per share of $0.02, compared to analyst estimates of $0.04 per share. For Q2, the Company said that it expected $470 million in sales, compared to estimates of $483.76 million, but cautioned that revenue could come in well below estimates. On this news, Palantir's stock price fell $2.02 per share, or 21.31%, to close at $7.46 per share on May 9, 2022.

If you are aware of any facts relating to this investigation or purchasedPalantir shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/pltr. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC





View source version on accesswire.com:

https://www.accesswire.com/700978/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Palantir-Technologies-Inc-PLTR-Investigation



comtex tracking

COMTEX_407100910/2457/2022-05-12T11:01:34

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.